L-Vax: A Feasibility Study Using a DNP-Modified Autologous Tumor Cell Vaccine as Therapy in Patients With Resectable Non-Small Cell Lung Cancer

NCT00298298 Phase 1/Phase 2 TERMINATED

To determine if a vaccine made from patient's own tumor tissue can stimulate an immune response against the patient's tumor cells. To determine the safety of the vaccine

Details

Lead sponsor	AVAX Technologies
Phase	Phase 1/Phase 2
Status	TERMINATED
Enrolment	6
Start date	2006-01
Completion	2014-01

Conditions

• Non-Small Cell Lung Cancer - Completely Resectable

Interventions

• L-Vax: Autologous, DNP-Modified NSCLC Vaccine

Primary outcomes

• Cell-mediated immunity to autologous tumor cells. — 3 months
• Safety — 1 year

Countries

United States